A Novel, Orally Bioavailable Nociceptin Receptor Antagonist, LY2940094, Reduces Ethanol Self-Administration and Ethanol Seeking in Animal Models.
Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana.
School of Pharmacy, Pharmacology Unit, University of Camerino, Camerino, Italy.
Eli Lilly and Company, Madrid, Spain.
Department of Molecular and Cellular Neurosciences, The Scripps Research Institute, La Jolla, California.
- Published Article
Alcoholism Clinical and Experimental Research
Wiley (Blackwell Publishing)
- Publication Date
Apr 30, 2016
Our findings demonstrate for the first time that blockade of NOP receptors attenuates ethanol self-administration and ethanol-motivated behaviors, stress-induced ethanol seeking, and ethanol-induced stimulation of brain reward pathways in lines of rats that exhibit excessive ethanol consumption. Results suggest that LY2940094 may have potential therapeutic utility in treating alcohol addiction.
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 06/09/2018 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/27084498